Michael O'Neill is a seasoned pharmaceutical product development expert with extensive experience in drug discovery and development, particularly in oncology and neuroscience. Currently the Owner of Nomon Bio Ltd since April 2019, Michael has also been the Director of R&D at Inflection Biosciences Ltd since February 2012, focusing on innovative drug development and transitioning candidates to readiness for phase I studies. Prior roles include Managing Director at Eolas Biosciences Ltd, where Michael provided strategic and business development advice, and Senior Research Scientist at Eli Lilly & Co, where Michael advanced drug discovery programs. Michael's educational background includes a PhD in Psychology from Queen's University Belfast and a Diploma in Executive Coaching and Organisational Development.
This person is not in any teams
This person is not in any offices